Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.11T
Market cap1.11T
Price-Earnings ratio
40.26
Price-Earnings ratio40.26
Dividend yield
0.56%
Dividend yield0.56%
Average volume
2.32M
Average volume2.32M
High today
$1,192.94
High today$1,192.94
Low today
$1,168.47
Low today$1,168.47
Open price
$1,185.76
Open price$1,185.76
Volume
855.69K
Volume855.69K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$716.08
52 Week low$716.08

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,183.70, giving the company a market capitalization of 1.11T. It carries a P/E multiple of 40.26 and pays a dividend yield of 0.56%.

On 2026-09-29, Eli Lilly(LLY) stock traded between a low of $1,168.47 and a high of $1,192.94. Shares are currently priced at $1,183.70, which is +1.3% above the low and -0.8% below the high.

The Eli Lilly(LLY)'s current trading volume is 855.69K, compared to an average daily volume of 2.32M.

During the past year, Eli Lilly(LLY) stock moved between $716.08 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $716.08 at its lowest and $1,292.65 at its peak.

LLY News

Benzinga 1h
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide

Novo Nordisk A/S (NYSE:NVO) announced on Tuesday new real-world evidence demonstrating that escalating semaglutide dosage reduces major adverse cardiovascular e...

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide
TipRanks 2h
Lilly Advances Next-Gen Obesity Combo, Setting Up New Catalyst for LLY

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. This Phase 2 study, officially titled “A Phase 2, Parallel-Group, Double-Blind...

Benzinga 5h
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data

Eli Lilly and Co. (NYSE:LLY) revealed new analysis data indicating that its medications, Zepbound and Foundayo, yielded superior weight loss and blood sugar con...

Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Benzinga 6h
Eli Lilly Launches Global Push to Expand Weight-Loss and Diabetes Drug Access in Lower Income Countries

Eli Lilly and Company (NYSE: LLY) launched the Lilly Change the Course Commitment on Monday, a global health initiative aiming to treat as many people with diab...

Eli Lilly Launches Global Push to Expand Weight-Loss and Diabetes Drug Access in Lower Income Countries
Zacks 6h
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of cou...

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
TipRanks 7h
Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

Eli Lilly (LLY) announced results from a new analysis showing that Zepbound – tirzepatide – 10 mg and 15 mg, a dual GIP and GLP-1 receptor agonist, delivered gr...

Nasdaq 10h
Lilly's Foundayo Outperforms Oral Semaglutide In New Diabetes Analysis

(RTTNews) - Tuesday, Eli Lilly (LLY) said Foundayo 17.2 mg showed greater weight loss and A1C reductions than oral semaglutide 25 mg in an indirect treatment co...

Lilly's Foundayo Outperforms Oral Semaglutide In New Diabetes Analysis
TipRanks 1d
Eli Lilly CEO tells Bloomberg sees more deals in untapped areas

Eli Lilly (LLY) CEO Dave Ricks said in an interview with Bloomberg that he sees the company doing more deals in untapped areas and sees deals that are “a little...

Benzinga 1d
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss

The U.S. Food and Drug Administration granted expanded approval to Eli Lilly and Co.’s (NYSE:LLY) Olumiant (baricitinib), allowing adolescents aged 12 and older...

FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
The Motley Fool 1d
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Investing in a top company can offer safety and stability, but oftentimes, the potential upside can also be limited. Take Eli Lilly (LLY +0.13%) as a prime exam...

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.